眼科用医薬品の世界市場：洞察、競合情勢、市場予測：2030年

世界の眼科用医薬品市場は、2022年には350億9,530万米ドルとなりました。同市場は、2024年から2030年までの予測期間中に5.34%のCAGRで拡大し、2030年には477億9,478万米ドルに達すると予測されています。世界の高齢者人口の増加、白内障、緑内障、眼アレルギー、感染症などの様々な眼疾患や問題の症例の増加、世界中の眼科用医薬品分野における臨床試験や製品開発活動の増加などにより、眼科用医薬品市場はプラスの市場成長を遂げており、予測期間中（2024年～2030年）に眼科用医薬品市場の収益が大きく伸びると予測されます。

眼科用医薬品市場の成長要因の1つは、世界の高齢者人口の増加です。WHOが提供したデータ（2023年）によると、2020年には世界中で約10億人が60歳以上でした。上記の情報源は、2050年までに60歳以上の高齢者人口は倍増し、約21億人になると予測しています。また、80歳以上の人口は2020年から2050年の間に3倍に増え、4億2,600万人に達すると推定されています。

高齢者では、白内障、加齢黄斑変性症（AMD）、緑内障、糖尿病性網膜症、老眼アレルギー、感染症などが視力低下の主な原因であり、これらの疾患はいずれも早期に診断されれば、適切な眼科治療薬を用いて治療するか、進行を遅らせることができます。

当レポートでは、世界の眼科用医薬品市場について調査し、市場の概要とともに、製品タイプ別、適応症別、薬剤クラス別、剤形別、地域別動向、および市場に参入する企業のプロファイルなどを提供しています。

目次

第1章 眼科用医薬品市場レポートのイントロダクション

第2章 眼科用医薬品市場のエグゼクティブサマリー

第3章 規制分析

第4章 眼科用医薬品市場の主な要因分析

• 眼科用医薬品市場の促進要因
• 眼科用医薬品市場の抑制要因と課題
• 眼科用医薬品市場の機会

第5章 眼科用医薬品市場におけるポーターのファイブフォース分析

第6章 眼科用医薬品市場へのCOVID-19の影響分析

第7章 眼科用医薬品市場の概要

• 製品タイプ別
• 適応症別
• 薬剤クラス別
• 剤形別
• 地域別

第8章 眼科用医薬品市場の企業と製品プロファイル

• Novartis AG
• Pfizer Inc.
• Abbvie, Inc.
• F. Hoffmann-La Roche Ltd.
• Thea Pharma Inc.
• Bausch Health Companies
• Alcon
• Viatris Inc.
• Regeneron Pharmaceuticals
• Bayer AG
• Santen Inc.
• Sun Pharmaceutical Industries, Inc.
• Teva Pharmaceutical Industries Ltd.
• Amring Pharmaceutical Inc.
• Merck & Co., Inc.
• Coherus Biosciences
• Nicox
• Akorn Operating Company LLC
• Senju Pharmaceutical Co., Ltd
• Adenovir

第9章 KOL の見解

第10章 プロジェクトのアプローチ

第11章 DelveInsightについて

第12章 免責事項とお問い合わせ

List of Tables

• Table 1: Competitive Analysis
• Table 2: COVID-19 Impact Analysis on Ophthalmic Drugs Market
• Table 3: Ophthalmic Drugs Market Analysis in Global (2021-2030)
• Table 4: Ophthalmic Drugs Market Analysis in Global by Product Type (2021-2030)
• Table 5: Ophthalmic Drugs Market Analysis in Global by Indication (2021-2030)
• Table 6: Ophthalmic Drugs Market Analysis in Global by Drug Class (2021-2030)
• Table 7: Ophthalmic Drugs Market Analysis in Global by Dosage Forms (2021-2030)
• Table 8: Ophthalmic Drugs Market Analysis in Global by Geography (2021-2030)
• Table 9: Ophthalmic Drugs Market Analysis in North America (2021-2030)
• Table 10: Ophthalmic Drugs Market Analysis in North America by Country (2021-2030)
• Table 11: Ophthalmic Drugs Market Analysis in the US (2021-2030)
• Table 12: Ophthalmic Drugs Market Analysis in Canada (2021-2030)
• Table 13: Ophthalmic Drugs Market Analysis in Mexico (2021-2030)
• Table 14: Ophthalmic Drugs Market Analysis in Europe (2021-2030)
• Table 15: Ophthalmic Drugs Market Analysis in Europe by Country (2021-2030)
• Table 16: Ophthalmic Drugs Market Analysis in France (2021-2030)
• Table 17: Ophthalmic Drugs Market Analysis in Germany (2021-2030)
• Table 18: Ophthalmic Drugs Market Analysis in the UK (2021-2030)
• Table 19: Ophthalmic Drugs Market Analysis in Italy (2021-2030)
• Table 20: Ophthalmic Drugs Market Analysis in Spain (2021-2030)
• Table 21: Ophthalmic Drugs Market Analysis in the Rest of Europe (2021-2030)
• Table 22: Ophthalmic Drugs Market Analysis in Asia-Pacific (2021-2030)
• Table 23: Ophthalmic Drugs Market Analysis in Asia-Pacific by Country (2021-2030)
• Table 24: Ophthalmic Drugs Market Analysis in China (2021-2030)
• Table 25: Ophthalmic Drugs Market Analysis in Japan (2021-2030)
• Table 26: Ophthalmic Drugs Market Analysis in India (2021-2030)
• Table 27: Ophthalmic Drugs Market Analysis in Australia (2021-2030)
• Table 28: Ophthalmic Drugs Market Analysis in South Korea (2021-2030)
• Table 29: Ophthalmic Drugs Market Analysis in the Rest of Asia-Pacific (2021-2030)
• Table 30: Ophthalmic Drugs Market Analysis in the Rest of the World (2021-2030)
• Table 31: Ophthalmic Drugs Market Analysis in the Rest of the World by Region (2021-2030)
• Table 32: Ophthalmic Drugs Market Analysis in the Middle East (2021-2030)
• Table 33: Ophthalmic Drugs Market Analysis in Africa (2021-2030)
• Table 34: Ophthalmic Drugs Market Analysis in South America (2021-2030)

List of Figures

• Figure 1: Competitive Analysis
• Figure 2: COVID-19 Impact Analysis on Ophthalmic Drugs Market
• Figure 3: Ophthalmic Drugs Market Analysis in Global (2021-2030)
• Figure 4: Ophthalmic Drugs Market Analysis in Global by Product Type (2021-2030)
• Figure 5: Ophthalmic Drugs Market Analysis in Global by Indication (2021-2030)
• Figure 6: Ophthalmic Drugs Market Analysis in Global by Drug Class (2021-2030)
• Figure 7: Ophthalmic Drugs Market Analysis in Global by Dosage Forms (2021-2030)
• Figure 8: Ophthalmic Drugs Market Analysis in Global by Geography (2021-2030)
• Figure 9: Ophthalmic Drugs Market Analysis in North America (2021-2030)
• Figure 10: Ophthalmic Drugs Market Analysis in North America by Country (2021-2030)
• Figure 11: Ophthalmic Drugs Market Analysis in the US (2021-2030)
• Figure 12: Ophthalmic Drugs Market Analysis in Canada (2021-2030)
• Figure 13: Ophthalmic Drugs Market Analysis in Mexico (2021-2030)
• Figure 14: Ophthalmic Drugs Market Analysis in Europe (2021-2030)
• Figure 15: Ophthalmic Drugs Market Analysis in Europe by Country (2021-2030)
• Figure 16: Ophthalmic Drugs Market Analysis in France (2021-2030)
• Figure 17: Ophthalmic Drugs Market Analysis in Germany (2021-2030)
• Figure 18: Ophthalmic Drugs Market Analysis in the UK (2021-2030)
• Figure 19: Ophthalmic Drugs Market Analysis in Italy (2021-2030)
• Figure 20: Ophthalmic Drugs Market Analysis in Spain (2021-2030)
• Figure 21: Ophthalmic Drugs Market Analysis in the Rest of Europe (2021-2030)
• Figure 22: Ophthalmic Drugs Market Analysis in Asia-Pacific (2021-2030)
• Figure 23: Ophthalmic Drugs Market Analysis in Asia-Pacific by Country (2021-2030)
• Figure 24: Ophthalmic Drugs Market Analysis in China (2021-2030)
• Figure 25: Ophthalmic Drugs Market Analysis in Japan (2021-2030)
• Figure 26: Ophthalmic Drugs Market Analysis in India (2021-2030)
• Figure 27: Ophthalmic Drugs Market Analysis in Australia (2021-2030)
• Figure 28: Ophthalmic Drugs Market Analysis in South Korea (2021-2030)
• Figure 29: Ophthalmic Drugs Market Analysis in the Rest of Asia-Pacific (2021-2030)
• Figure 30: Ophthalmic Drugs Market Analysis in the Rest of the World (2021-2030)
• Figure 31: Ophthalmic Drugs Market Analysis in the Rest of the World by Region (2021-2030)
• Figure 32: Ophthalmic Drugs Market Analysis in the Middle East (2021-2030)
• Figure 33: Ophthalmic Drugs Market Analysis in Africa (2021-2030)
• Figure 34: Ophthalmic Drugs Market Analysis in South America (2021-2030)
• Figure 35: Market Drivers
• Figure 36: Market Barriers
• Figure 37: Market Opportunities
• Figure 38: PORTER's Five Force Analysis

Ophthalmic Drugs Market By Product Type (Prescription Drugs And Over-The-Counter Drugs), By Indication (Dry Eyes, Eye Allergy, Glaucoma, Retinal Disorders, And Others), By Drug Class (Anti-Allergic, Anti-Inflammatory, Anti-Vegf Agents, And Others), By Dosage Forms (Gels, Capsules/Tablets, Eye Drops, And Others), and by geography is expected to advance at a respectable cagr forecast till 2030 owing to the rising burden of geriatric population globally, increase in the cases of various eye disorders and problems such as cataract, glaucoma, eye allergies, infections, among others and the increasing product development activities in the ophthalmic drugs arena across the globe.

The global ophthalmic drugs market was valued at USD 35,095.30 million in 2022 and is likely to register a CAGR of 5.34% during the forecast period from 2024 to 2030 to reach USD 47,794.78 million by 2030. The Ophthalmic Drugs market is observing optimistic market growth due to an increase in the rising burden of the geriatric population globally, the growing cases of various eye disorders and problems such as cataracts, glaucoma, eye allergies, infections, among others, increasing clinical trials and product development activities in the ophthalmic drugs arena across the globe is further expected to result in appreciable revenue growth of the Ophthalmic Drugs market during the forecast period (2024-2030).

Ophthalmic Drugs Market Dynamics:

One of the main factors for the growth of the ophthalmic drugs market is the increasing geriatric population globally. According to the data provided by the WHO (2023), in 2020, about one billion people across the world were over the age of 60. The source mentioned above added by stating that by 2050, the elderly population aged 60 and above is expected to double in number representing about 2.1 billion people. Also, people in the age group of 80 and above are estimated to triple between 2020 and 2050 to reach 426 million.

In the elderly, cataracts, age-related macular degeneration (AMD), glaucoma, diabetic retinopathy, presbyopia allergies, and infections, among others are the major causes of vision loss, and each of these conditions can be either treated or slowed using suitable ophthalmic drugs if diagnosed early.

According to the World Health Organization (2023), globally 2.2 billion people had a near or distance vision impairment in 2020 out of which in at least 1 billion cases, vision impairment could have been prevented or was yet to be addressed.

Due to such bodily changes with age, a significant increase in the old age population can be directly linked to an increase in the population suffering from various ophthalmic diseases. Therefore, the rising geriatric population requiring more medications would spur the market demand for ophthalmic drugs during the forecast period (2024-2030)

However, certain side effects associated with the use of eye drops, gels, ointments, and strict regulatory guidelines by the government cause delay in product approvals which may act as restraints for the ophthalmic drugs market growth.

The ophthalmic drugs market was moderately impacted during the COVID-19 pandemic. During the initial stage of the pandemic, the sale of ophthalmic drugs suffered a downfall owing to the imposition of strict lockdown rules, and disruption in the manufacturing, and supply of the drugs. Also, during the pandemic, COVID-19 patients were given more preference in terms of diagnosis and treatment, and this led to a decreased number of diagnoses and treatments for various ophthalmic conditions such as cataracts, dry eyes, glaucoma, macular degeneration, conjunctivitis, and others which in turn lead to the decreased demand for ophthalmic drugs, negatively impacting the growth of ophthalmic drugs market. However, with the ease of lockdown restrictions, an upturn of resources, and a supply chain, with the administration of the vaccine to the public, with the incorporation of telemedicine and e-commerce, and with the increasing number of diagnoses for ophthalmic diseases through telehealth, the demand for ophthalmic drugs is up and is expected to grow during the forecast period from 2022 - 2028.

Ophthalmic Drugs Market Segment Analysis:

Ophthalmic Drugs Market by product type (prescription drugs and over-the-counter drugs), indication (dry eyes, eye allergy, glaucoma, retinal disorders, and others), drug class (anti-allergic, anti-inflammatory, anti-VEGF agents, and others) dosage forms (gels, capsules/tablets, eye drops, and others), and geography (North America, Europe, Asia-Pacific, and Rest of the World).

In the dosage forms segment of the ophthalmic drugs market, the eye drops segment is expected to have a significant revenue share in the year 2023. This can be attributed to their wide applicability in a variety of diseases along with the rising drug development activities such as drug launches and regulatory approvals for eye drops during the forecast period. Eye drops mainly contain a saline base which can provide moisture for the eyes and can also help to pull the redness out. They also contain medicinal ingredients in cases of eye drops recommended for vision impairments such as refractive errors and others such as glaucoma, cataract, etc. Doctors and ophthalmologists use eye drops to treat conjunctivitis, glaucoma, keratitis, and eye allergies, and also before cataract and corneal surgery.

In January 2022, Alcon, the global leader in eye care announced the European launch of the newest addition to its innovative portfolio of dry eye products - Systane®Complete Preservative-Free Lubricant Eye Drops. In a similar instance, in October 2022, Allergan, an AbbVie company, announced the U.S. Food and Drug Administration (FDA) approval of VUITY(TM) (pilocarpine HCl ophthalmic solution) 1.25% for the treatment of presbyopia, which is the first and only FDA-approved eye drop to treat this common and progressive eye condition.

Therefore, owing to the aforementioned factors, it is expected that the demand for eye drops will increase, thereby propelling the overall market for ophthalmic drugs during the forecast period from 2022-2028.

North America is expected to dominate the overall Ophthalmic Drugs Market:

Among all the regions, North America is expected to dominate the global Ophthalmic Drugs market in the year 2023 and is expected to do the same during the forecast period from 2024-2030. This domination is due to the rising prevalence of eye disorders such as cataracts, diabetic retinopathy, and other eye-related disorder, also the increasing geriatric population, and the rising product launches in North America region is further expected to drive the market growth during the forecast period.

According to the National Eye Institute (2023), the United States recorded 7.7 million diabetic retinopathy cases and 24 million cataract cases in 2020, and it is expected to reach 11.3 million and 38 million, respectively, by 2030. The American Association of Ophthalmology states that cataract is the major cause of visual impairment worldwide, and geriatric ophthalmic issues are emerging as prime factors in other developing countries apart from the North America region.

Along with the growing patient population associated with eye disorders, product development activities are further expected to bolster the demand for ophthalmic drugs in the upcoming years in the region.

In April 2022, Novartis' Sandoz expanded its eye drug offerings, targeting a popular ocular hypertension medication from AbbVie's Allergan. Sandoz launched the generic version of AbbVie's Combigan, a combo eye drop used for the treatment of elevated eye pressure, as the most-dispensed branded combo glaucoma medication, in the U.S.. Therefore, the interplay of various factors such as the presence of a large patient population, as well as product launches by key market players in the region is expected to boost the North American ophthalmic drugs market during the forecast period. Therefore, the interplay of the above-mentioned factors would provide a conducive growth environment for the North America Ophthalmic Drugs market during the forecast period.

Ophthalmic Drugs Market Key Players:

Some of the key market players operating in the Ophthalmic Drugs Market include Novartis AG, Pfizer Inc., Abbvie, Inc., F. Hofmann-La Roche Ltd., Thea Pharma Inc., Bausch Health Companies Inc., Alcon, Viatris Inc., Regeneron Pharmaceuticals, Inc., Bayer AG, Santen Inc., Sun Pharmaceutical Industries, Inc., Teva Pharmaceutical Industries Ltd., Amring Pharmaceuticals Inc., Merck & Co. Inc., Coherus Biosciences, Nicox, Akorn Operating Company LLC, Senju Pharmaceutical Co., Ltd, Adenovir Pharma, and others.

Recent Developmental Activities in the Ophthalmic Drugs Market:

In June 2022, Novartis announced the acquisition of Kedalion Therapeutics and its AcuStream(TM) technology, an innovative device that may have the potential to facilitate precise dosing and accurate delivery of certain topical ophthalmic medications to the eye.

In April 2022, Sandoz, a Novartis division, announced the US launch of the generic combination eyedrop brimonidine tartrate/timolol maleate ophthalmic solution 0.2%/0.5%, an AB-rated generic equivalent to AbbVie's COMBIGAN, to lower eye pressure in patients with ocular hypertension.

In January 2020, Horizon Therapeutics' Tepezza® (teprotumumab-trbw) injection was approved by the FDA for the treatment of Thyroid Eye Disease (TED). The Tepezza injection active, a human monoclonal antibody and targeted inhibitor of a specific growth factor receptor, is the only product approved in the US to treat the rare autoimmune disorder of TED.

Key Takeaways from the Ophthalmic Drugs Market Report Study

• Market size analysis for current Ophthalmic Drugs Market size (2023), and market forecast for 5 years (2024-2030)
• The effect of the COVID-19 pandemic on this market is significant. To capture and analyze suitable indicators, our experts are closely watching the Ophthalmic Drugs market.
• Top key product/services/technology developments, mergers, acquisitions, partnerships, and joint ventures happened for the last 3 years
• Key companies dominating the global Ophthalmic Drugs market.
• Various opportunities are available for the other competitor in the Ophthalmic Drugs Market space.
• What are the top-performing segments in 2023? How these segments will perform in 2030.
• Which are the top-performing regions and countries in the current ophthalmic drugs Market scenario?
• Which are the regions and countries where companies should have concentrated on opportunities for ophthalmic drugs market growth in the coming future?

Target Audience who can be benefited from this Ophthalmic Drugs Market Report Study

• Ophthalmic Drugs providers
• Research and development organizations
• Ophthalmic-related organizations, associations, forums, and other alliances
• Government and corporate offices
• Start-up companies, venture capitalists, and private equity firms
• Distributors and Traders dealing in Ophthalmic Drugs
• Various end users who want to know more about the ophthalmic drugs market and the latest innovations in the Ophthalmic Drugs market.

Frequently Asked Questions for Ophthalmic Drugs Market:

1. What are Ophthalmic Drugs?

An ophthalmic drug is administered into the eye, most frequently in the form of an eye drop formulation. To treat a variety of eye diseases, topical formulations are used. These conditions might include dry eye, glaucoma, eye damage from bacteria, and bacterial infections.

2. What is the global market for Ophthalmic Drugs?

The global ophthalmic drugs market was valued at USD 35,095.30 million in 2022 and is likely to register a CAGR of 5.34% during the forecast period from 2024 to 2030 to reach USD 47,794.78 million by 2030.

3. What are the drivers for the global Ophthalmic Drugs market?

The Ophthalmic Drugs market is witnessing positive growth due to an increase in the rising burden of the geriatric population globally, the growing cases of various eye disorders and problems such as cataracts, glaucoma, eye allergies, infections, among others, increasing clinical trials and product development activities in the ophthalmic drugs arena across the globe is further expected to result in appreciable revenue growth of the Ophthalmic Drugs market during the forecast period (2024-2030).

4. Who are the key players operating in the global Ophthalmic Drugs market?

Some of the key market players operating in the Ophthalmic Drugs Market are Novartis AG, Pfizer Inc., Abbvie, Inc., F. Hofmann-La Roche Ltd., Thea Pharma Inc., Bausch Health Companies Inc., Alcon, Viatris Inc., Regeneron Pharmaceuticals, Inc., Bayer AG, Santen Inc., Sun Pharmaceutical Industries, Inc., Teva Pharmaceutical Industries Ltd., Amring Pharmaceuticals Inc., Merck & Co. Inc., Coherus Biosciences, Nicox, Akorn Operating Company LLC, Senju Pharmaceutical Co., Ltd, Adenovir Pharma, and others.

5. Which region has the highest share in the Ophthalmic Drugs market?

Among all the regions, North America is estimated to amass a significant revenue share in the global Ophthalmic Drugs market. This domination is owing to the rising prevalence of eye disorders such as cataracts, and diabetic retinopathy, the increasing geriatric population, and the rising product launch in various geographies, among others.

Table of Contents

1.Ophthalmic Drugs Market Report Introduction

2. Ophthalmic Drugs Market Executive Summary

• 2.1. Scope of the Study
• 2.2. Market at Glance
• 2.3. Competitive Assessment

3. Regulatory Analysis

4. Ophthalmic Drugs Market Key Factors Analysis

• 4.1. Ophthalmic Drugs Market Drivers
  • 4.1.1. The rising burden of the geriatric population globally
  • 4.1.2. Increase in the cases of various eye disorders and problems such as cataracts, glaucoma, eye allergies, and infections, among others.
  • 4.1.3. The growing number of clinical trials and product development activities in the ophthalmic drugs arena.
• 4.2. Ophthalmic Drugs Market Restraints and Challenges
  • 4.2.1. Side effects associated with the use of eye drops, gels, ointments, and others
  • 4.2.2. Stringent regulatory guidelines
• 4.3. Ophthalmic Drugs Market Opportunities
  • 4.3.1. Improving drug safety and biocompatibility
  • 4.3.2. The untapped potential of emerging markets and the rising eye health initiatives by government bodies mainly in developing countries

5. Ophthalmic Drugs Market Porter's Five Forces Analysis

• 5.1. Bargaining Power of Suppliers
• 5.2. Bargaining Power of Consumers
• 5.3. Threat of New Entrants
• 5.4. Threat of Substitutes
• 5.5. Competitive Rivalry

6. COVID-19 Impact Analysis on Ophthalmic Drugs Market

7. Ophthalmic Drugs Market Layout

• 7.1. By Product Type
  • 7.1.1. Prescription Drugs
  • 7.1.2. Over-the-counter (OTC) Drugs
• 7.2. By Indication
  • 7.2.1. Dry Eyes
  • 7.2.2. Eye Allergy
  • 7.2.3. Glaucoma
  • 7.2.4. Retinal Disorders
  • 7.2.5. Others
• 7.3. By Drug Class
  • 7.3.1. Anti-allergic
  • 7.3.2. Anti-inflammatory
  • 7.3.3. Anti-VEGF agents
  • 7.3.4. Others
• 7.4. By Dosage Forms
  • 7.4.1. Gels
  • 7.4.2. Capsules/Tablets
  • 7.4.3. Eye drops
  • 7.4.4. Others
• 7.5. By Geography
  • 7.5.1. North America
    • 7.5.1.1. United States Ophthalmic Drugs Market in USD million (2021-2030)
    • 7.5.1.2. Canada Ophthalmic Drugs Market in USD million (2021-2030)
    • 7.5.1.3. Mexico Ophthalmic Drugs Market in USD million (2021-2030)
  • 7.5.2. Europe
    • 7.5.2.1. France Ophthalmic Drugs Market in USD million (2021-2030)
    • 7.5.2.2. Germany Ophthalmic Drugs Market in USD million (2021-2030)
    • 7.5.2.3. United Kingdom Ophthalmic Drugs Market in USD million (2021-2030)
    • 7.5.2.4. Italy Ophthalmic Drugs Market in USD million (2021-2030)
    • 7.5.2.5. Spain Ophthalmic Drugs Market in USD million (2021-2030)
    • 7.5.2.6. Rest of Europe Ophthalmic Drugs Market in USD million (2021-2030)
  • 7.5.3. Asia-Pacific
    • 7.5.3.1. China Ophthalmic Drugs Market in USD million (2021-2030)
    • 7.5.3.2. Japan Ophthalmic Drugs Market in USD million (2021-2030)
    • 7.5.3.3. India Ophthalmic Drugs Market in USD million (2021-2030)
    • 7.5.3.4. Australia Ophthalmic Drugs Market in USD million (2021-2030)
    • 7.5.3.5. South Korea Ophthalmic Drugs Market in USD million (2021-2030)
    • 7.5.3.6. Rest of Asia Pacific Ophthalmic Drugs Market in USD million (2021-2030)
  • 7.5.4. Rest of the World (RoW)
    • 7.5.4.1. Middle East Ophthalmic Drugs Market in USD million (2021-2030)
    • 7.5.4.2. Africa Ophthalmic Drugs Market in USD million (2021-2030)
    • 7.5.4.3. South America Ophthalmic Drugs Market in USD million (2021-2030)

8. Ophthalmic Drugs Market Company and Product Profiles

• 8.1. Novartis AG
  • 8.1.1. Company Overview
  • 8.1.2. Company Snapshot
  • 8.1.3. Financial Overview
  • 8.1.4. Product Listing
  • 8.1.5. Entropy
• 8.2. Pfizer Inc.
  • 8.2.1. Company Overview
  • 8.2.2. Company Snapshot
  • 8.2.3. Financial Overview
  • 8.2.4. Product Listing
  • 8.2.5. Entropy
• 8.3. Abbvie, Inc.
  • 8.3.1. Company Overview
  • 8.3.2. Company Snapshot
  • 8.3.3. Financial Overview
  • 8.3.4. Product Listing
  • 8.3.5. Entropy
• 8.4. F. Hoffmann-La Roche Ltd.
  • 8.4.1. Company Overview
  • 8.4.2. Company Snapshot
  • 8.4.3. Financial Overview
  • 8.4.4. Product Listing
  • 8.4.5. Entropy
• 8.5. Thea Pharma Inc.
  • 8.5.1. Company Overview
  • 8.5.2. Company Snapshot
  • 8.5.3. Financial Overview
  • 8.5.4. Product Listing
  • 8.5.5. Entropy
• 8.6. Bausch Health Companies
  • 8.6.1. Company Overview
  • 8.6.2. Company Snapshot
  • 8.6.3. Financial Overview
  • 8.6.4. Product Listing
  • 8.6.5. Entropy
• 8.7. Alcon
  • 8.7.1. Company Overview
  • 8.7.2. Company Snapshot
  • 8.7.3. Financial Overview
  • 8.7.4. Product Listing
  • 8.7.5. Entropy
• 8.8. Viatris Inc.
  • 8.8.1. Company Overview
  • 8.8.2. Company Snapshot
  • 8.8.3. Financial Overview
  • 8.8.4. Product Listing
  • 8.8.5. Entropy
• 8.9. Regeneron Pharmaceuticals
  • 8.9.1. Company Overview
  • 8.9.2. Company Snapshot
  • 8.9.3. Financial Overview
  • 8.9.4. Product Listing
  • 8.9.5. Entropy
• 8.10. Bayer AG
  • 8.10.1. Company Overview
  • 8.10.2. Company Snapshot
  • 8.10.3. Financial Overview
  • 8.10.4. Product Listing
  • 8.10.5. Entropy
• 8.11. Santen Inc.
  • 8.11.1. Company Overview
  • 8.11.2. Company Snapshot
  • 8.11.3. Financial Overview
  • 8.11.4. Product Listing
  • 8.11.5. Entropy
• 8.12. Sun Pharmaceutical Industries, Inc.
  • 8.12.1. Company Overview
  • 8.12.2. Company Snapshot
  • 8.12.3. Financial Overview
  • 8.12.4. Product Listing
  • 8.12.5. Entropy
• 8.13. Teva Pharmaceutical Industries Ltd.
  • 8.13.1. Company Overview
  • 8.13.2. Company Snapshot
  • 8.13.3. Financial Overview
  • 8.13.4. Product Listing
  • 8.13.5. Entropy
• 8.14. Amring Pharmaceutical Inc.
  • 8.14.1. Company Overview
  • 8.14.2. Company Snapshot
  • 8.14.3. Financial Overview
  • 8.14.4. Product Listing
  • 8.14.5. Entropy
• 8.15. Merck & Co., Inc.
  • 8.15.1. Company Overview
  • 8.15.2. Company Snapshot
  • 8.15.3. Financial Overview
  • 8.15.4. Product Listing
  • 8.15.5. Entropy
• 8.16. Coherus Biosciences
  • 8.16.1. Company Overview
  • 8.16.2. Company Snapshot
  • 8.16.3. Financial Overview
  • 8.16.4. Product Listing
  • 8.16.5. Entropy
• 8.17. Nicox
  • 8.17.1. Company Overview
  • 8.17.2. Company Snapshot
  • 8.17.3. Financial Overview
  • 8.17.4. Product Listing
  • 8.17.5. Entropy
• 8.18. Akorn Operating Company LLC
  • 8.18.1. Company Overview
  • 8.18.2. Company Snapshot
  • 8.18.3. Financial Overview
  • 8.18.4. Product Listing
  • 8.18.5. Entropy
• 8.19. Senju Pharmaceutical Co., Ltd
  • 8.19.1. Company Overview
  • 8.19.2. Company Snapshot
  • 8.19.3. Financial Overview
  • 8.19.4. Product Listing
  • 8.19.5. Entropy
• 8.20. Adenovir
  • 8.20.1. Company Overview
  • 8.20.2. Company Snapshot
  • 8.20.3. Financial Overview
  • 8.20.4. Product Listing
  • 8.20.5. Entropy

9. KOL Views

10. Project Approach

11. About DelveInsight

12. Disclaimer & Contact Us